Revision Military LIMITED

Revision Military LIMITED, a for-profit manufacturer of advanced protective equipment and medical supplies based in Essex Junction, Vermont, operates as a prime contractor supplying specialized military eyewear, optical products, and analytical equipment to the Defense Department on a full-and-open basis with no set-aside designations. The company is a subsidiary of Galvion Inc. and competes across 1,758 total awards with combined potential value of $1.21 billion, nearly all (100%) as a prime contractor.

Revision Military's customer base concentrates heavily on medical supply procurement. The Defense Logistics Agency Troop Support Medical dominates the award portfolio with 1,500 delivery orders worth $127.8 million combined potential value—a commanding 96% of all awards tracked. This concentration reflects Revision Military's primary federal role: supplying Ultra Performance Liquid Chromatography (UPLC) units and carrier lens prescriptions to DLA Troop Support Medical through a series of fixed-price delivery orders with economic price adjustment terms. Representative delivery orders include a $54.7 million UPLC 10-pack award (January 2026), a $109,440 single-pack UPLC order (September 2025), and a $49,752 10-pack delivery (September 2024). Beyond the DLA's medical supply work, Revision Military holds secondary customer relationships with the Department of Homeland Security US Coast Guard (123 awards, $454 thousand), the Department of the Army Materiel Command Sustainment Command (12 awards, $9.9 million), and the Department of the Army Materiel Command Research Development and Engineering Command (12 awards, $11.8 million). A secondary customer pairing—DLA Troop Support Clothing and Textiles—anchors $21.1 million in combined value across just two awards, signaling large-dollar procurements outside the core medical supply stream.

Revision Military places task orders under five primary indefinite delivery vehicles. The largest is Indefinite Delivery Contract SPM2DE13D7558 with 794 task orders carrying $12.4 million combined potential value; Indefinite Delivery Contract SPE2DE21D0044 supports 458 task orders worth $9.8 million; Indefinite Delivery Contract SPM2DE08D7538 funds 161 task orders valued at $5.2 million; Indefinite Delivery Contract SPM2DE11D7552 carries 80 task orders for $2.7 million; and Indefinite Delivery Contract 70Z02318DMNQ07400 covers 103 task orders at $414 thousand. These vehicles represent the delivery-order infrastructure through which DLA Troop Support Medical places its recurring medical supply requirements.

Beyond delivery-order work, Revision Military holds two Other Transaction Agreement (OTA) IDVs with the Department of the Army Materiel Command Research Development and Engineering Command valued at $1.49 million and $137,113.50. The larger OTA, awarded October 2023, focuses on development of enhanced ballistic protective eyewear prototypes; the smaller, awarded September 2021 as a multiple-award vehicle, supports prototype development for enhanced ballistic spectacles and visors. A single definitive contract from the Army Combat Capabilities Development Command Soldier Center, valued at $863,510 and awarded February 2025, funds research and development to improve enhanced ballistic protection eyewear systems through integration of advanced technologies into hybrid protective eyewear, with completion scheduled for February 2027. This R&D footprint demonstrates that Revision Military operates across both mature supply-chain delivery-order work and advanced prototype development, though the latter remains a small fraction of overall federal engagement.

Revision Military's capability footprint centers on manufacturing and supplying specialized analytical medical equipment (particularly UPLC systems), ballistic and laser protective eyewear, optical products including carrier lens prescriptions, and safety glasses. Award data shows concentration in Laboratory Equipment and Supplies (1,200 awards), Medical and Surgical Instruments (280 awards), Safety and Rescue Equipment (95 awards), and Sporting and Athletic Goods Manufacturing (108 awards). The company's primary NAICS codes align with Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (1,367 awards) and Surgical and Medical Instrument Manufacturing (162 awards), reflecting a wholesale and manufacturing posture serving defense logistics.

Activity has remained relatively stable across the past five years—101 awards in 2022, 95 in 2023, 106 in 2024, 120 in 2025, and 29 year-to-date in 2026—with no significant growth trajectory but consistent federal engagement. The recompete cliff over the next twenty-four months shows minimal exposure: only three awards with combined potential value of $6.5 million face completion in that window, suggesting Revision Military's core delivery-order work operates under indefinite vehicles with rolling task-order issuance rather than discrete contract expiration risk.

Revision Military operates a minimal subcontractor footprint. One sub-award is recorded: work under Bluehalo, LLC as prime, dated May 2024, for personnel protection against ocular threats involving production capabilities for advanced eye protection and automation of fabrication systems. This reflects Revision Military's secondary role on specialized protective-equipment development rather than core federal business posture.